Business Description
Gain Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US36269B1052
Description
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 15.67 | |||||
| Equity-to-Asset | 0.62 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -28.6 | |||||
| 3-Year EBITDA Growth Rate | -9.6 | |||||
| 3-Year EPS without NRI Growth Rate | -8.9 | |||||
| 3-Year FCF Growth Rate | -6.1 | |||||
| 3-Year Book Growth Rate | 12.4 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.23 | |||||
| 9-Day RSI | 43.82 | |||||
| 14-Day RSI | 44.04 | |||||
| 3-1 Month Momentum % | 74.41 | |||||
| 6-1 Month Momentum % | 5.98 | |||||
| 12-1 Month Momentum % | -18.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.99 | |||||
| Quick Ratio | 2.99 | |||||
| Cash Ratio | 2.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.7 | |||||
| Shareholder Yield % | -41.77 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -38325.45 | |||||
| ROE % | -216.95 | |||||
| ROA % | -132.15 | |||||
| ROIC % | -1037.1 | |||||
| 3-Year ROIIC % | -1403.52 | |||||
| ROC (Joel Greenblatt) % | -4201.37 | |||||
| ROCE % | -198.36 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 455 | |||||
| PB Ratio | 5.31 | |||||
| Price-to-Tangible-Book | 5 | |||||
| EV-to-EBIT | -1.69 | |||||
| EV-to-Forward-EBIT | -1.33 | |||||
| EV-to-EBITDA | -1.7 | |||||
| EV-to-Revenue | 658.18 | |||||
| EV-to-Forward-Revenue | 237.68 | |||||
| EV-to-FCF | -1.72 | |||||
| Price-to-GF-Value | 0.91 | |||||
| Price-to-Net-Current-Asset-Value | 5.31 | |||||
| Price-to-Net-Cash | 6.8 | |||||
| Earnings Yield (Greenblatt) % | -59.17 | |||||
| FCF Yield % | -43.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GANX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gain Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.055 | ||
| EPS (TTM) ($) | -1.1 | ||
| Beta | 0.38 | ||
| 3-Year Sharpe Ratio | -0.24 | ||
| 3-Year Sortino Ratio | -0.37 | ||
| Volatility % | 119.57 | ||
| 14-Day RSI | 44.04 | ||
| 14-Day ATR ($) | 0.202978 | ||
| 20-Day SMA ($) | 1.77325 | ||
| 12-1 Month Momentum % | -18.57 | ||
| 52-Week Range ($) | 0.89 - 5.33 | ||
| Shares Outstanding (Mil) | 26.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gain Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gain Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Gain Therapeutics Inc Frequently Asked Questions
What is Gain Therapeutics Inc(GANX)'s stock price today?
The current price of GANX is $1.70. The 52 week high of GANX is $5.33 and 52 week low is $0.89.
When is next earnings date of Gain Therapeutics Inc(GANX)?
The next earnings date of Gain Therapeutics Inc(GANX) is 2025-03-26 Est..
Does Gain Therapeutics Inc(GANX) pay dividends? If so, how much?
Gain Therapeutics Inc(GANX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers